reports
- Kate Heseltine
SynBiotic - Platform primed for growth
SynBiotic has built up a leading platform company that spans the hemp and cannabis industry to cover the full value chain, from cultivation through to sales. Management buys and builds ventures that create and market hemp, cannabis and cannabinoid products for both medical and recreational use, while continually seeking investments in exciting new verticals. Recreational cannabis use has recently been partially legalised in Germany, while the same legislative changes have benefited the medicinal...
- Kate Heseltine
SynBiotic - Building the platform
SynBiotic’s management has created a platform that spans the value chain in the cannabis and cannabinoid space, from cultivation and labs to distribution. SynBiotic’s business creates and markets cannabis and cannabinoid products, which have both medical and consumer applications, with management constantly looking to add to its portfolio. We believe SynBiotic is well-placed to benefit from any relaxation in legislation around cannabis and cannabinoid products in Germany, as per the published go...
- Kate Heseltine
SynBiotic - Management update – on track
SynBiotic has extended its lead in the European hemp and cannabis sector and is continuing to build a cannabis ‘ecosystem’, encompassing cultivation, production and trade. Based on preliminary figures, SynBiotic has delivered pro forma sales of €15m for FY21, in line with management guidance. The company has now added a target of becoming profitable as of FY23. Full consolidated financial statements will be presented at the AGM, planned in Q4.
- Kate Heseltine
SynBiotic - Further acquisitions
SynBiotic has announced it is acquiring 50.1% of the shares of several market-leading hemp companies, which are part of hemp industry pioneer Daniel Kruse’s group of companies. There will be a capital increase in kind to fund these acquisitions and €2m in cash will be contributed to the capital reserves of the companies being acquired. This marks another step in SynBiotic’s buy-and-build strategy, whereby management is using its experience in scaling profitable companies to accelerate SynBiotic’...
- Kate Heseltine
SynBiotic - Further acquisitions
SynBiotic has announced it is acquiring 50.1% of the shares of several market-leading hemp companies, which are part of hemp industry pioneer Daniel Kruse’s group of companies. There will be a capital increase in kind to fund these acquisitions and €2m in cash will be contributed to the capital reserves of the companies being acquired. This marks another step in SynBiotic’s buy-and-build strategy, whereby management is using its experience in scaling profitable companies to accelerate SynBiotic’...
- Kate Heseltine
SynBiotic - Building a cannabis platform
Management plans to utilise its experience in scaling profitable companies to accelerate SynBiotic’s strategy and become a leading platform company in the cannabinoids industry. It acquired SolidMind Group in June 2020, followed by subsequent smaller deals, and we expect further M&A activity as the platform grows. Increasing consumer acceptance of cannabinoids across a range of applications (from healthcare to wellbeing) ensures a huge target market. New product sources (both cannabinoids and pl...
- Kate Heseltine
SynBiotic - Building a cannabis platform
Management plans to utilise its experience in scaling profitable companies to accelerate SynBiotic’s strategy and become a leading platform company in the cannabinoids industry. It acquired SolidMind Group in June 2020, followed by subsequent smaller deals, and we expect further M&A activity as the platform grows. Increasing consumer acceptance of cannabinoids across a range of applications (from healthcare to wellbeing) ensures a huge target market. New product sources (both cannabinoids and pl...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.